Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CON vs LFST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: CON 5 – 1 LFST Matrix Metrics: CON 9 – 1 LFST

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over LifeStance Health Group, Inc. (LFST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas LFST carries 36.9/100 (SELL) at $13.82 (30.8x Forward P/E, 6.4% operating margin).

  • Growth vs. Quality Trade-Off: CON earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. LFST 36.9/100 SELL) and 0.52β · 38% Vol risk profile, whereas LFST leads top-line expansion (+25.3% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CON vs LFST
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66
LFST NASDAQ
LifeStance Health Group, Inc. Common Stock
Services-Health Services
$13.82
+3.6% 1D
Market Cap $5.1B
TTM Revenue $1.68B
Forward P/E 30.8x
Beta / 30D Vol 0.68β · 45% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 38.0 Fund 35.0 Flow 50.0 Mom 11.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 54
RSI-14: 53.6 · SMA20: $13.80 · SMA50: $12.90

6-Pillar Scorecard Institutional Category Breakdown (CON 5 – 1 LFST)

Columns: Metric · CON · LFST
1. Valuation Multiples CON
Forward P/E 22.0x 30.8x
Trailing P/E 24.5x 74.1x
PEG Ratio N/M N/M
EV / Revenue 3.1x 3.0x
2. Growth & Scale CON
Revenue Growth (YoY) +8.6% +25.3%
Earnings Growth (YoY) +36.4% N/A
TTM Revenue (USD) $2.34B $1.68B
Market Cap $5.2B $5.1B
3. Profitability & Quality CON
Gross Margin 29.9% 34.4%
Operating Margin 17.2% 6.4%
Net Profit Margin 9.3% 4.3%
Return on Equity (ROE) 47.2% 4.8%
4. Balance Sheet & Cash Flow CON
Cash Generation (TTM) $257M $164M EBITDA
Cash Flow Margin 11.0% 9.8% EBITDA Mgn
Net Cash / Leverage $2.04B Net Debt (4.20x D/E) $3.92 Book/Sh · 4.8% ROE
Dividend Yield 0.60% None (0.00%)
5. Options & Positioning CON
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 269.9% (95th %ile) 42.6% (50th %ile)
Put/Call OI Skew 0.79x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat LFST
OpEx & R&D Intensity 12.7% of Rev ($297M) 28.0% of Rev ($470M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CON (9) vs LFST (1)
Institutional Metric CON LFST Criterion Row Edge
Market Capitalization
Scale
$5.2B $5.1B Larger Scale CON
Trailing P/E Ratio
Valuation
24.5x 74.1x Lower Multiple CON
Forward P/E Ratio
Valuation
22.0x 30.8x Lower Multiple CON
Revenue Growth (YoY)
Growth
+8.6% +25.3% Higher Growth LFST
Operating Margin (TTM)
Profitability
17.2% 6.4% Higher Margin CON
Net Profit Margin
Profitability
9.3% 4.3% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
47.2% 4.8% Higher ROE CON
52-Week Range Position
Momentum
91% ($19–$44) 81% ($6–$16) Stronger Trend CON
Beta / 30D Volatility
Risk Regime
0.52β · 38% Vol 0.68β · 45% Vol Lower Realized Risk CON
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 36.9 / 100 (SELL) Higher Composite CON
Trailing 12M Revenue (USD)
Operating Scale
$2.34B $1.68B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.9% 34.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$257M ($2.04B Net Debt (4.20x D/E)) $164M EBITDA ($3.92 Book/Sh · 4.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LFST +5.35 pp
CON: +4.68% · LFST: +10.03%
3M Horizon CON +5.93 pp
CON: +19.58% · LFST: +13.65%
6M Horizon LFST +21.77 pp
CON: +65.24% · LFST: +87.01%
1Y Horizon LFST +6.04 pp
CON: +117.58% · LFST: +123.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CON vs LFST. Trailing 12-month operating profitability (CON 17.2% vs LFST 6.4%) and valuation multiples (CON 22.0x vs LFST 30.8x Forward P/E) are benchmarked directly in Pillar 4 below.

CON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.34B
Gross Margin29.9%
Op. Margin17.2%
ROE / Fwd P/E47.2% · 22.0x
LFST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.68B
Gross Margin34.4%
Op. Margin6.4%
ROE / Fwd P/E4.8% · 30.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LFST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.6%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LFST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published
LFST Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.1B market capitalization and 6.4% operating margin.
OpEx & R&D Reinvestment 28.0% of Rev ($470M)
90D Engineering Disclosures 0 Published

Investor FAQ CON vs LFST Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over LifeStance Health Group, Inc. (LFST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas LFST carries 36.9/100 (SELL) at $13.82 (30.8x Forward P/E, 6.4% operating margin). Growth vs. Quality Trade-Off: CON earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. LFST 36.9/100 SELL) and 0.52β · 38% Vol risk profile, whereas LFST leads top-line expansion (+25.3% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with LFST at +25.3% YoY revenue growth and N/A YoY earnings growth on $1.68B TTM revenue (34.4% gross margin, 6.4% operating margin). On trailing 12-month operating scale, CON generates $2.34B in USD-normalized revenue versus $1.68B for LFST. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 28.0% of Rev ($470M) (0 disclosures) for LFST.

CON screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas LFST trades at 30.8x Forward P/E, 74.1x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (9.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus LFST (4.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, LFST carries 42.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.